Skip to main content

Table 4 Relationship between anti-C1q antibody and other disease parameters among patients under study

From: Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Variable
n (%) or mean ± SD
Positive
Anti-C1q
(n = 34)
Negative
Anti-C1q
(n = 46)
t/x2 P value
Clinical features Arthritis 31 (91.2) 41 (89.1) 0.091 0.763
Pleurisy 15 (35.7) 27 (58.7) 1.666 0.197
Fever 19 (55.9) 20 (43.5) 1.204 0.273
Malar rash 20 (58.8) 30 (65.2) 0.341 0.559
Oral ulcers 17 (50.0) 21 (45.7) 0.148 0.700
Alopecia 13 (38.2) 21 (61.8) 0.440 0.507
Photosensitivity 11 (32.4) 20 (43.5) 1.020 0.313
Neurologic manifestations 6 (17.6) 14 (30.4) 1.705 0.192
APS 6 (17.6) 13 (28.3) 1.216 0.270
Vasculitis 10 (29.4) 4 (8.7) 5.811 0.016
Pericarditis 5 (14.7) 5 (10.9) 0.263 0.608
Discoid rash 4 (11.8) 2 (4.3) 1.550 0.213
Myositis 0 (0.0) 1 (2.2) 0.748 0.387
Nephritis 23 (67.6) 17 (37.0) 7.366 0.007
ECLAM   4.2 ± 1.9 3.5 ± 2.2 1.572 0.120
Laboratory features ESR (mm/1st hour) 57.7 ± 32.5 41.1 ± 26.8 2.500 0.015
Serum creatinine (μmol/L) 0.9 ± 0.7 0.8 ± 0.3 0.643 0.500
Serum albumin (g/dl) 3.6 ± 0.5 4.0 ± 0.8 2.677 0.009
Low C3 < 90 (mg/dl) 20 (58.8) 16 (34.8) 4.565 0.033
Low C4 < 10 (mg/dl) 12 (35.3) 7 (15.2) 4.351 0.037
  1. APS Antiphospholipid syndrome, ESR Erythrocyte sedimentation rate, ECLAM European Consensus Lupus Activity Measurement